Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies

Su-Hyun Kim; Hyunmin Jang; Na Young Park; Yeseul Kim; So-Yeon Kim; Min Young Lee; Jae-Won Hyun; Ho Jin Kim

doi:10.1212/NXI.0000000000000947

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

893

See original article:

Errata - July 01, 2021

Article Figures & Data

Figures

Tables

Download figure

Open in new tab

Download powerpoint

Figure Temporal Association of Clinical Relapse With Discontinuation of Immunosuppressive Therapy and AQP4 Antibody Status in 6 Patients With Neuromyelitis Optica Spectrum Disorder
N, AQP4 antibody negative, 1–4+ semiquantitative AQP4 antibody positive score. AQP4 = aquaporin-4; AZA = azathioprine; MMF = mycophenolate mofetil.

Tables

Figures

Download figure

Open in new tab

Download powerpoint

Download figure

Open in new tab

Download powerpoint

links.lww.com/NXI/A380

Letters: Rapid online correspondence

No comments have been published for this article.

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
Submit only on articles published within 6 months of issue date.
Do not be redundant. Read any comments already posted on the article prior to submission.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Authors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.nn.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Main menu

User menu

Search

Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies